{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T01:06:17Z","timestamp":1794013577645,"version":"4.8.0"},"reference-count":166,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["1P01CA214278"],"award-info":[{"award-number":["1P01CA214278"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA226983"],"award-info":[{"award-number":["R01CA226983"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1038\/s41591-022-01765-8","type":"journal-article","created":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T15:16:46Z","timestamp":1650381406000},"page":"678-689","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":270,"title":["Engineered cellular immunotherapies in cancer and beyond"],"prefix":"10.1038","volume":"28","author":[{"given":"Amanda V.","family":"Finck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Blanchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Roselle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Golinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0241-3557","authenticated-orcid":false,"given":"Carl H.","family":"June","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,19]]},"reference":[{"key":"1765_CR1","unstructured":"Combination Products (FDA, accessed 1 March 2022); https:\/\/www.fda.gov\/combination-products"},{"key":"1765_CR2","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp,S. A. et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368, 1509\u20131518 (2013).","journal-title":"N. Engl. J. Med."},{"key":"1765_CR3","doi-asserted-by":"publisher","first-page":"179ps177","DOI":"10.1126\/scitranslmed.3005568","volume":"5","author":"MA Fischbach","year":"2013","unstructured":"Fischbach, M. A., Bluestone, J. A. & Lim, W. A. Cell-based therapeutics: the next pillar of medicine. Sci. Transl. Med 5, 179ps177 (2013).","journal-title":"Sci. Transl. Med"},{"key":"1765_CR4","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1056\/NEJMoa2031054","volume":"384","author":"H Frangoul","year":"2021","unstructured":"Frangoul, H. et al. CRISPR\u2013Cas9 gene editing for sickle cell disease and \u03b2-thalassemia. N. Engl. J. Med. 384, 252\u2013260 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1765_CR5","unstructured":"Approved Cellular and Gene Therapy (FDA, 2022); https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/approved-cellular-and-gene-therapy-products"},{"key":"1765_CR6","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1056\/NEJMra1913421","volume":"385","author":"J Elisseeff","year":"2021","unstructured":"Elisseeff, J., Badylak, S. F. & Boeke, J. D. Immune and genome engineering as the future of transplantable tissue. N. Engl. J. Med. 385, 2451\u20132462 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1765_CR7","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1016\/S0140-6736(20)32334-5","volume":"396","author":"R Benjamin","year":"2020","unstructured":"Benjamin, R. et al. Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. Lancet 396, 1885\u20131894 (2020).","journal-title":"Lancet"},{"key":"1765_CR8","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/hdy.1951.38","volume":"5","author":"D Anderson","year":"1951","unstructured":"Anderson, D., Billingham, R. E., Lampkin, G. H. & Medawar, P. B. The use of skin grafting to distinguish between monozygotic and dizygotic twins in cattle. Heredity 5, 379\u2013397 (1951).","journal-title":"Heredity"},{"key":"1765_CR9","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/j.1600-6143.2006.01621.x","volume":"7","author":"M Mart\u00ednez\u2010Llordella","year":"2007","unstructured":"Mart\u00ednez\u2010Llordella, M. et al. Multiparameter immune profiling of operational tolerance in liver transplantation. Am. J. Transplant. 7, 309\u2013319 (2007).","journal-title":"Am. J. Transplant."},{"key":"1765_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen, D. S. & Mellman, I. Oncology meets immunology: the cancer\u2013immunity cycle. Immunity 39, 1\u201310 (2013).","journal-title":"Immunity"},{"key":"1765_CR11","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1158\/1078-0432.CCR-14-1860","volume":"21","author":"GL Beatty","year":"2015","unstructured":"Beatty, G. L. & Gladney, W. L. Immune escape mechanisms as a guide for cancer immunotherapy. Clin. Cancer Res. 21, 687\u2013692 (2015).","journal-title":"Clin. Cancer Res."},{"key":"1765_CR12","first-page":"291","volume":"7","author":"G Cudkowicz","year":"1964","unstructured":"Cudkowicz, G. & Stimpfling, J. Deficient growth of C57bl marrow cells transplanted in F1 hybrid mice: association with the histocompatibility-2 locus. Immunology 7, 291 (1964).","journal-title":"Immunology"},{"key":"1765_CR13","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1084\/jem.166.5.1499","volume":"166","author":"WJ Murphy","year":"1987","unstructured":"Murphy, W. J., Kumar, V. & Bennett, M. Acute rejection of murine bone marrow allografts by natural killer cells and T cells. Differences in kinetics and target antigens recognized. J. Exp. Med. 166, 1499\u20131509 (1987).","journal-title":"J. Exp. Med."},{"key":"1765_CR14","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1002\/eji.1830070915","volume":"7","author":"R Kiessling","year":"1977","unstructured":"Kiessling, R. et al. Evidence for a similar or common mechanism for natural killer cell activity and resistance to hemopoietic grafts. Eur. J. Immunol. 7, 655\u2013663 (1977).","journal-title":"Eur. J. Immunol."},{"key":"1765_CR15","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1126\/science.1068440","volume":"295","author":"L Ruggeri","year":"2002","unstructured":"Ruggeri, L. et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295, 2097\u20132100 (2002).","journal-title":"Science"},{"key":"1765_CR16","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nri2154","volume":"7","author":"ND Huntington","year":"2007","unstructured":"Huntington, N. D., Vosshenrich, C. A. & Di Santo, J. P. Developmental pathways that generate natural-killer-cell diversity in mice and humans. Nat. Rev. Immunol. 7, 703\u2013714 (2007).","journal-title":"Nat. Rev. Immunol."},{"key":"1765_CR17","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.4049\/jimmunol.1501804","volume":"195","author":"DH Raulet","year":"2015","unstructured":"Raulet, D. H. Bone marrow cell rejection, MHC, NK cells, and missing self recognition: ain\u2019t that peculiar (with apologies to Marvin Gaye). J. Immunol. 195, 2923\u20132925 (2015).","journal-title":"J. Immunol."},{"key":"1765_CR18","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.4049\/jimmunol.1102997","volume":"188","author":"W Liu","year":"2012","unstructured":"Liu, W., Xiao, X., Demirci, G., Madsen, J. & Li, X. C. Innate NK cells and macrophages recognize and reject allogeneic nonself in vivo via different mechanisms. J. Immunol. 188, 2703\u20132711 (2012).","journal-title":"J. Immunol."},{"key":"1765_CR19","doi-asserted-by":"publisher","first-page":"582","DOI":"10.3389\/fimmu.2016.00582","volume":"7","author":"J Marino","year":"2016","unstructured":"Marino, J., Paster, J. & Benichou, G. Allorecognition by T lymphocytes and allograft rejection. Front. Immunol. 7, 582 (2016).","journal-title":"Front. Immunol."},{"key":"1765_CR20","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.4049\/jimmunol.1700219","volume":"201","author":"Y Kanda","year":"2018","unstructured":"Kanda, Y. et al. Visualizing the rapid and dynamic elimination of allogeneic T cells in secondary lymphoid organs. J. Immunol. 201, 1062\u20131072 (2018).","journal-title":"J. Immunol."},{"key":"1765_CR21","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.3389\/fimmu.2019.01195","volume":"10","author":"Y Kitazawa","year":"2019","unstructured":"Kitazawa, Y. et al. Novel targeting to XCR1+ dendritic cells using allogeneic T cells for polytopical antibody responses in the lymph nodes. Front. Immunol. 10, 1195 (2019).","journal-title":"Front. Immunol."},{"key":"1765_CR22","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June, C. H. & Sadelain, M. Chimeric antigen receptor therapy. N. Engl. J. Med. 379, 64\u201373 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1765_CR23","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/ni1102-991","volume":"3","author":"GP Dunn","year":"2002","unstructured":"Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J. & Schreiber, R. D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3, 991\u2013998 (2002).","journal-title":"Nat. Immunol."},{"key":"1765_CR24","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/j.1365-2141.2009.07886.x","volume":"147","author":"O Ringd\u00e9n","year":"2009","unstructured":"Ringd\u00e9n, O., Karlsson, H., Olsson, R., Omazic, B. & Uhlin, M. The allogeneic graft\u2010versus\u2010cancer effect. Br. J. Haematol. 147, 614\u2013633 (2009).","journal-title":"Br. J. Haematol."},{"key":"1765_CR25","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/s41591-019-0472-9","volume":"25","author":"AG Chapuis","year":"2019","unstructured":"Chapuis, A. G. et al. T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant. Nat. Med 25, 1064\u20131072 (2019).","journal-title":"Nat. Med"},{"key":"1765_CR26","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.immuni.2018.03.024","volume":"48","author":"Q Wei","year":"2018","unstructured":"Wei, Q. & Frenette, P. S. Niches for hematopoietic stem cells and their progeny. Immunity 48, 632\u2013648 (2018).","journal-title":"Immunity"},{"key":"1765_CR27","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/MOH.0000000000000265","volume":"23","author":"VW Yu","year":"2016","unstructured":"Yu, V. W. & Scadden, D. T. Heterogeneity of the bone marrow niche. Curr. Opin. Hematol. 23, 331 (2016).","journal-title":"Curr. Opin. Hematol."},{"key":"1765_CR28","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1200\/JCO.20.00475","volume":"39","author":"S Khaldoyanidi","year":"2021","unstructured":"Khaldoyanidi, S., Nagorsen, D., Stein, A., Ossenkoppele, G. & Subklewe, M. Immune biology of acute myeloid leukemia: implications for immunotherapy. J. Clin. Oncol. 39, 419\u2013432 (2021).","journal-title":"J. Clin. Oncol."},{"key":"1765_CR29","doi-asserted-by":"publisher","first-page":"11842","DOI":"10.1073\/pnas.2034201100","volume":"100","author":"E Passegu\u00e9","year":"2003","unstructured":"Passegu\u00e9, E., Jamieson, C. H., Ailles, L. E. & Weissman, I. L. Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics? Proc. Natl Acad. Sci. USA 100, 11842\u201311849 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1765_CR30","doi-asserted-by":"publisher","first-page":"4262","DOI":"10.1172\/JCI84813","volume":"126","author":"PJ Paszkiewicz","year":"2016","unstructured":"Paszkiewicz, P. J. et al. Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia. J. Clin. Invest. 126, 4262\u20134272 (2016).","journal-title":"J. Clin. Invest."},{"key":"1765_CR31","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","volume":"602","author":"JJ Melenhorst","year":"2022","unstructured":"Melenhorst, J. J. et al. Decade-long remissions of leukemia sustained by the persistence of activated CD4+\u2009CAR T-cells. Nature 602, 503\u2013509 (2022).","journal-title":"Nature"},{"key":"1765_CR32","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1126\/science.aav8692","volume":"365","author":"L Ma","year":"2019","unstructured":"Ma, L. et al. Enhanced CAR\u2013T cell activity against solid tumors by vaccine boosting through the chimeric receptor. Science 365, 162\u2013168 (2019).","journal-title":"Science"},{"key":"1765_CR33","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1126\/science.aay5967","volume":"367","author":"K Reinhard","year":"2020","unstructured":"Reinhard, K. et al. An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors. Science 367, 446\u2013453 (2020).","journal-title":"Science"},{"key":"1765_CR34","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ccr.2012.02.022","volume":"21","author":"D Hanahan","year":"2012","unstructured":"Hanahan, D. & Coussens L. M. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21, 309\u2013322 (2012).","journal-title":"Cancer Cell"},{"key":"1765_CR35","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1146\/annurev-bioeng-071813-105259","volume":"16","author":"RK Jain","year":"2014","unstructured":"Jain, R. K., Martin, J. D. & Stylianopoulos, T. The role of mechanical forces in tumor growth and therapy. Annu. Rev. Biomed. Eng. 16, 321\u2013346 (2014).","journal-title":"Annu. Rev. Biomed. Eng."},{"key":"1765_CR36","doi-asserted-by":"publisher","first-page":"5289","DOI":"10.1158\/1078-0432.CCR-21-1171","volume":"27","author":"SJ Seitter","year":"2021","unstructured":"Seitter, S. J. et al. Impact of prior treatment on the efficacy of adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma. Clin. Cancer Res. 27, 5289\u20135298 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1765_CR37","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/nm.3833","volume":"21","author":"I Caruana","year":"2015","unstructured":"Caruana, I. et al. Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nat. Med. 21, 524\u2013529 (2015).","journal-title":"Nat. Med."},{"key":"1765_CR38","doi-asserted-by":"publisher","first-page":"20201013","DOI":"10.1098\/rsif.2020.1013","volume":"18","author":"LV Brown","year":"2021","unstructured":"Brown, L. V., Gaffney, E. A., Ager, A., Wagg, J. & Coles, M. C. Quantifying the limits of CAR T-cell delivery in mice and men. J. R. Soc. Interface 18, 20201013 (2021).","journal-title":"J. R. Soc. Interface"},{"key":"1765_CR39","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/s41591-019-0564-6","volume":"25","author":"RG Majzner","year":"2019","unstructured":"Majzner, R. G. & Mackall, C. L. Clinical lessons learned from the first leg of the CAR T cell journey. Nat. Med. 25, 1341\u20131355 (2019).","journal-title":"Nat. Med."},{"key":"1765_CR40","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.ccell.2018.03.012","volume":"33","author":"DS Thommen","year":"2018","unstructured":"Thommen, D. S. & Schumacher, T. N. T cell dysfunction in cancer. Cancer Cell 33, 547\u2013562 (2018).","journal-title":"Cancer Cell"},{"key":"1765_CR41","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.it.2015.02.008","volume":"36","author":"KE Pauken","year":"2015","unstructured":"Pauken, K. E. & Wherry, E. J. Overcoming T cell exhaustion in infection and cancer. Trends Immunol. 36, 265\u2013276 (2015).","journal-title":"Trends Immunol."},{"key":"1765_CR42","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ccell.2020.07.005","volume":"38","author":"M Hong","year":"2020","unstructured":"Hong, M., Clubb, J. D. & Chen, Y. Y. Engineering CAR-T cells for next-generation cancer therapy. Cancer Cell 38, 473\u2013488 (2020).","journal-title":"Cancer Cell"},{"key":"1765_CR43","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","volume":"19","author":"CU Blank","year":"2019","unstructured":"Blank, C. U. et al. Defining \u2018T cell exhaustion\u2019. Nat. Rev. Immunol. 19, 665\u2013674 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"1765_CR44","doi-asserted-by":"publisher","first-page":"6081","DOI":"10.1016\/j.cell.2021.11.016","volume":"184","author":"CR Good","year":"2021","unstructured":"Good, C. R. et al. An NK-like CAR T cell transition in CAR T cell dysfunction. Cell 184, 6081\u20136100 (2021).","journal-title":"Cell"},{"key":"1765_CR45","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nm.4321","volume":"23","author":"CH June","year":"2017","unstructured":"June, C. H., Warshauer, J. T. & Bluestone, J. A. Is autoimmunity the Achilles\u2019 heel of cancer immunotherapy? Nat. Med 23, 540\u2013547 (2017).","journal-title":"Nat. Med"},{"key":"1765_CR46","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transpl. 25, 625\u2013638 (2019).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"1765_CR47","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41409-020-01134-4","volume":"56","author":"VS Sheth","year":"2021","unstructured":"Sheth, V. S. & Gauthier, J. Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL. Bone Marrow Transplant. 56, 552\u2013566 (2021).","journal-title":"Bone Marrow Transplant."},{"key":"1765_CR48","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1158\/2159-8290.CD-17-1368","volume":"8","author":"A Taraseviciute","year":"2018","unstructured":"Taraseviciute, A. et al. Chimeric antigen receptor t cell-mediated neurotoxicity in nonhuman primates. Cancer Discov. 8, 750\u2013763 (2018).","journal-title":"Cancer Discov."},{"key":"1765_CR49","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.cell.2020.08.022","volume":"183","author":"KR Parker","year":"2020","unstructured":"Parker, K. R. et al. Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies. Cell 183, 126\u2013142.e117 (2020).","journal-title":"Cell"},{"key":"1765_CR50","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/j.ccell.2021.11.005","volume":"39","author":"CA Lareau","year":"2021","unstructured":"Lareau, C. A., Parker, K. R. & Satpathy, A. T. Charting the tumor antigen maps drawn by single-cell genomics. Cancer Cell 39, 1553\u20131557 (2021).","journal-title":"Cancer Cell"},{"key":"1765_CR51","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1038\/s41591-021-01564-7","volume":"27","author":"O Van Oekelen","year":"2021","unstructured":"Van Oekelen, O. et al. Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy. Nat. Med. 27, 2099\u20132103 (2021).","journal-title":"Nat. Med."},{"key":"1765_CR52","doi-asserted-by":"publisher","first-page":"197ra103","DOI":"10.1126\/scitranslmed.3006034","volume":"5","author":"BJ Cameron","year":"2013","unstructured":"Cameron, B. J. et al. Identification of a titin-derived HLA-A1\u2013presented peptide as a cross-reactive target for engineered MAGE A3\u2013directed T cells. Sci. Transl. Med. 5, 197ra103 (2013).","journal-title":"Sci. Transl. Med."},{"key":"1765_CR53","doi-asserted-by":"publisher","first-page":"150","DOI":"10.36401\/JIPO-21-2","volume":"4","author":"K Tang","year":"2021","unstructured":"Tang, K. & Nastoupil, L. J. Real-world experiences of CAR T-cell therapy for large B-cell lymphoma: how similar are they to the prospective studies? J. Immunother. Precis. Oncol. 4, 150\u2013159 (2021).","journal-title":"J. Immunother. Precis. Oncol."},{"key":"1765_CR54","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/s41576-020-00298-5","volume":"22","author":"G Ferrari","year":"2021","unstructured":"Ferrari, G., Thrasher, A. J. & Aiuti, A. Gene therapy using haematopoietic stem and progenitor cells. Nat. Rev. Genet. 22, 216\u2013234 (2021).","journal-title":"Nat. Rev. Genet."},{"key":"1765_CR55","doi-asserted-by":"publisher","first-page":"132Ra153","DOI":"10.1126\/scitranslmed.3003761","volume":"4","author":"J Scholler","year":"2012","unstructured":"Scholler, J. et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci. Transl. Med. 4, 132Ra153 (2012).","journal-title":"Sci. Transl. Med."},{"key":"1765_CR56","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1182\/blood.2021010858","volume":"138","author":"KP Micklethwaite","year":"2021","unstructured":"Micklethwaite, K. P. et al. Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells. Blood 138, 1391\u20131405 (2021).","journal-title":"Blood"},{"key":"1765_CR57","first-page":"631","volume":"292","author":"A Schambach","year":"2021","unstructured":"Schambach, A., Morgan, M. & Fehse, B. Two cases of T cell lymphoma following Piggybac-mediated CAR T cell therapy. Mol. Ther. 292, 631\u2013633 (2021).","journal-title":"Mol. Ther."},{"key":"1765_CR58","doi-asserted-by":"publisher","first-page":"eaba7365","DOI":"10.1126\/science.aba7365","volume":"367","author":"EA Stadtmauer","year":"2020","unstructured":"Stadtmauer, E. A. et al. CRISPR-engineered T cells in patients with refractory cancer. Science 367, eaba7365 (2020).","journal-title":"Science"},{"key":"1765_CR59","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.stemcr.2015.01.006","volume":"4","author":"S Nori","year":"2015","unstructured":"Nori, S. et al. Long-term safety issues of iPSC-based cell therapy in a spinal cord injury model: oncogenic transformation with epithelial-mesenchymal transition. Stem Cell Rep. 4, 360\u2013373 (2015).","journal-title":"Stem Cell Rep."},{"key":"1765_CR60","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/nrc3034","volume":"11","author":"U Ben-David","year":"2011","unstructured":"Ben-David, U. & Benvenisty, N. The tumorigenicity of human embryonic and induced pluripotent stem cells. Nat. Rev. Cancer 11, 268\u2013277 (2011).","journal-title":"Nat. Rev. Cancer"},{"key":"1765_CR61","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1126\/science.1124228","volume":"312","author":"J Hataye","year":"2006","unstructured":"Hataye, J., Moon, J. J., Khoruts, A., Reilly, C. & Jenkins, M. K. Naive and memory CD4+\u2009T cell survival controlled by clonal abundance. Science 312, 114\u2013116 (2006).","journal-title":"Science"},{"key":"1765_CR62","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1182\/blood-2007-12-128751","volume":"112","author":"S Newrzela","year":"2008","unstructured":"Newrzela, S. et al. Resistance of mature T cells to oncogene transformation. Blood 112, 2278\u20132286 (2008).","journal-title":"Blood"},{"key":"1765_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJM199001043220101","volume":"322","author":"JM Kaldor","year":"1990","unstructured":"Kaldor, J. M. et al. Leukemia following chemotherapy for ovarian cancer. N. Engl. J. Med 322, 1\u20136 (1990).","journal-title":"N. Engl. J. Med"},{"key":"1765_CR64","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s40425-017-0294-6","volume":"5","author":"A Ajina","year":"2017","unstructured":"Ajina, A. & Maher, J. Prospects for combined use of oncolytic viruses and CAR T-cells. J. Immunother. Cancer 5, 90 (2017).","journal-title":"J. Immunother. Cancer"},{"key":"1765_CR65","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.3389\/fimmu.2018.02460","volume":"9","author":"S Guedan","year":"2018","unstructured":"Guedan, S. & Alemany, R. CAR-T cells and oncolytic viruses: joining forces to overcome the solid tumor challenge. Front Immunol. 9, 2460 (2018).","journal-title":"Front Immunol."},{"key":"1765_CR66","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.omto.2021.11.014","volume":"23","author":"GWG Biegert","year":"2021","unstructured":"Biegert, G. W. G., Shaw, A. R. & Suzuki, M. Current development in adenoviral vectors for cancer immunotherapy. Mol. Ther. Oncolytics 23, 571\u2013581 (2021).","journal-title":"Mol. Ther. Oncolytics"},{"key":"1765_CR67","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","volume":"11","author":"PS Adusumilli","year":"2021","unstructured":"Adusumilli, P. S. et al. A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab. Cancer Discov. 11, 2748\u20132763 (2021).","journal-title":"Cancer Discov."},{"key":"1765_CR68","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1038\/s41587-019-0192-1","volume":"37","author":"BD Choi","year":"2019","unstructured":"Choi, B. D. et al. CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. Nat. Biotechnol. 37, 1049\u20131058 (2019).","journal-title":"Nat. Biotechnol."},{"key":"1765_CR69","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1038\/mt.2016.137","volume":"24","author":"M Siurala","year":"2016","unstructured":"Siurala, M. et al. Adenoviral delivery of tumor necrosis factor-alpha and interleukin-2 enables successful adoptive cell therapy of immunosuppressive melanoma. Mol. Ther. 24, 1435\u20131443 (2016).","journal-title":"Mol. Ther."},{"key":"1765_CR70","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1016\/j.ymthe.2017.09.010","volume":"25","author":"A Rosewell Shaw","year":"2017","unstructured":"Rosewell Shaw, A. et al. Adenovirotherapy delivering cytokine and checkpoint inhibitor augments CAR T Cells against metastatic head and neck cancer. Mol. Ther. 25, 2440\u20132451 (2017).","journal-title":"Mol. Ther."},{"key":"1765_CR71","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.ygyno.2013.06.003","volume":"130","author":"KH Kim","year":"2013","unstructured":"Kim, K. H. et al. A phase I clinical trial of Ad5\/3-\u220624, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer. Gynecol. Oncol. 130, 518\u2013524 (2013).","journal-title":"Gynecol. Oncol."},{"key":"1765_CR72","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40425-016-0121-5","volume":"4","author":"T Ranki","year":"2016","unstructured":"Ranki, T. et al. Phase I study with ONCOS-102 for the treatment of solid tumors \u2014 an evaluation of clinical response and exploratory analyses of immune markers. J. Immunother. Cancer 4, 17 (2016).","journal-title":"J. Immunother. Cancer"},{"key":"1765_CR73","doi-asserted-by":"crossref","unstructured":"Park, A.K., et al. Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors. Sci. Transl. Med. 12, eaaz1863 (2020).","DOI":"10.1126\/scitranslmed.aaz1863"},{"key":"1765_CR74","doi-asserted-by":"publisher","first-page":"e99573","DOI":"10.1172\/jci.insight.99573","volume":"3","author":"K Watanabe","year":"2018","unstructured":"Watanabe, K. et al. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses. JCI Insight 3, e99573 (2018).","journal-title":"JCI Insight"},{"key":"1765_CR75","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/nbt.4195","volume":"36","author":"S Rafiq","year":"2018","unstructured":"Rafiq, S. et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat. Biotechnol. 36, 847\u2013856 (2018).","journal-title":"Nat. Biotechnol."},{"key":"1765_CR76","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.blre.2015.11.003","volume":"30","author":"Y Xia","year":"2016","unstructured":"Xia, Y., Medeiros, L. J. & Young, K. H. Immune checkpoint blockade: releasing the brake towards hematological malignancies. Blood Rev. 30, 189\u2013200 (2016).","journal-title":"Blood Rev."},{"key":"1765_CR77","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.omto.2018.08.002","volume":"11","author":"Y Yin","year":"2018","unstructured":"Yin, Y. et al. Checkpoint blockade reverses anergy in IL-13R\u03b12 humanized scFv-based CAR T cells to treat murine and canine gliomas. Mol. Ther. Oncolytics 11, 20\u201338 (2018).","journal-title":"Mol. Ther. Oncolytics"},{"key":"1765_CR78","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1158\/2326-6066.CIR-17-0314","volume":"6","author":"A Wing","year":"2018","unstructured":"Wing, A. et al. Improving CAR T-cell therapy of solid tumors with oncolytic virus-driven production of a bispecific T-cell engager. Cancer Immunol. Res. 6, 605\u2013616 (2018).","journal-title":"Cancer Immunol. Res."},{"key":"1765_CR79","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1126\/science.175.4025.949","volume":"175","author":"T Friedmann","year":"1972","unstructured":"Friedmann, T. & Roblin, R. Gene therapy for human genetic disease? Science 175, 949\u2013955 (1972).","journal-title":"Science"},{"key":"1765_CR80","doi-asserted-by":"publisher","first-page":"a011692","DOI":"10.1101\/cshperspect.a011692","volume":"2","author":"TN Williams","year":"2012","unstructured":"Williams, T. N. & Weatherall, D. J. World distribution, population genetics, and health burden of the hemoglobinopathies. Cold Spring Harb. Perspect. Med. 2, a011692 (2012).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"1765_CR81","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/s41586-019-1841-8","volume":"576","author":"T Ndung\u2019u","year":"2019","unstructured":"Ndung\u2019u, T., McCune, J. M. & Deeks, S. G. Why and where an HIV cure is needed and how it might be achieved. Nature 576, 397\u2013405 (2019).","journal-title":"Nature"},{"key":"1765_CR82","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1089\/hum.2018.169","volume":"30","author":"S Pellenz","year":"2019","unstructured":"Pellenz, S. et al. New human chromosomal sites with \u201csafe harbor\u201d potential for targeted transgene insertion. Hum. Gene Ther. 30, 814\u2013828 (2019).","journal-title":"Hum. Gene Ther."},{"key":"1765_CR83","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.cell.2018.05.013","volume":"173","author":"MY Kim","year":"2018","unstructured":"Kim, M. Y. et al. Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia. Cell 173, 1439\u20131453.e1419 (2018).","journal-title":"Cell"},{"key":"1765_CR84","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1093\/genetics\/31.3.269","volume":"31","author":"T Dobzhansky","year":"1946","unstructured":"Dobzhansky, T. Genetics of natural populations. XIII. Recombination and variability in populations of Drosophila pseudoobscura. Genetics 31, 269 (1946).","journal-title":"Genetics"},{"key":"1765_CR85","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1158\/2159-8290.CD-20-1503","volume":"11","author":"J Setton","year":"2021","unstructured":"Setton, J. et al. Synthetic lethality in cancer therapeutics: the next generation. Cancer Discov. 11, 1626\u20131635 (2021).","journal-title":"Cancer Discov."},{"key":"1765_CR86","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917\u2013921 (2005).","journal-title":"Nature"},{"key":"1765_CR87","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1604958","volume":"375","author":"JM Zaretsky","year":"2016","unstructured":"Zaretsky, J. M. et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375, 819\u2013829 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1765_CR88","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1084\/jem.20172188","volume":"215","author":"CA Klebanoff","year":"2018","unstructured":"Klebanoff, C. A. & Wolchok, J. D. Shared cancer neoantigens: making private matters public. J. Exp. Med. 215, 5\u20137 (2018).","journal-title":"J. Exp. Med."},{"key":"1765_CR89","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","volume":"127","author":"JA Fraietta","year":"2016","unstructured":"Fraietta, J. A. et al. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood 127, 1117\u20131127 (2016).","journal-title":"Blood"},{"key":"1765_CR90","doi-asserted-by":"publisher","first-page":"13866","DOI":"10.1073\/pnas.231486598","volume":"98","author":"T Okazaki","year":"2001","unstructured":"Okazaki, T., Maeda, A., Nishimura, H., Kurosaki, T. & Honjo, T. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc. Natl Acad. Sci. USA 98, 13866\u201313871 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1765_CR91","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1158\/2326-6066.CIR-15-0048","volume":"3","author":"AJ Davenport","year":"2015","unstructured":"Davenport, A. J. et al. CAR-T cells inflict sequential killing of multiple tumor target cells. Cancer Immunol. Res. 3, 483\u2013494 (2015).","journal-title":"Cancer Immunol. Res."},{"key":"1765_CR92","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1158\/2159-8290.CD-19-0813","volume":"10","author":"N Singh","year":"2020","unstructured":"Singh, N. et al. Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T-cell dysfunction. Cancer Discov. 10, 552\u2013567 (2020).","journal-title":"Cancer Discov."},{"key":"1765_CR93","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","volume":"38","author":"M Klichinsky","year":"2020","unstructured":"Klichinsky, M. et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat. Biotechnol. 38, 947\u2013953 (2020).","journal-title":"Nat. Biotechnol."},{"key":"1765_CR94","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/s41576-021-00329-9","volume":"22","author":"GI Ellis","year":"2021","unstructured":"Ellis, G. I., Sheppard, N. C. & Riley, J. L. Genetic engineering of T cells for immunotherapy. Nat. Rev. Genet. 22, 427\u2013447 (2021).","journal-title":"Nat. Rev. Genet."},{"key":"1765_CR95","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1097\/COH.0000000000000665","volume":"16","author":"O Alfageme-Abello","year":"2021","unstructured":"Alfageme-Abello, O., Porret, R., Perreau, M., Perez, L. & Muller, Y. D. Chimeric antigen receptor T-cell therapy for HIV cure. Curr. Opin. HIV AIDS 16, 88\u201397 (2021).","journal-title":"Curr. Opin. HIV AIDS"},{"key":"1765_CR96","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1016\/j.jaci.2018.10.015","volume":"142","author":"JH Esensten","year":"2018","unstructured":"Esensten, J. H., Muller, Y. D., Bluestone, J. A. & Tang, Q. Regulatory T-cell therapy for autoimmune and autoinflammatory diseases: the next frontier. J. Allergy Clin. Immunol. 142, 1710\u20131718 (2018).","journal-title":"J. Allergy Clin. Immunol."},{"key":"1765_CR97","doi-asserted-by":"publisher","first-page":"100645","DOI":"10.1016\/j.blre.2019.100645","volume":"41","author":"M-H Haddadi","year":"2020","unstructured":"Haddadi, M.-H. et al. Autoimmunity as a target for chimeric immune receptor therapy: a new vision to therapeutic potential. Blood Rev. 41, 100645 (2020).","journal-title":"Blood Rev."},{"key":"1765_CR98","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1126\/science.aaf6756","volume":"353","author":"CT Ellebrecht","year":"2016","unstructured":"Ellebrecht, C. T. et al. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science 353, 179\u2013184 (2016).","journal-title":"Science"},{"key":"1765_CR99","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMc2107725","volume":"385","author":"D Mougiakakos","year":"2021","unstructured":"Mougiakakos, D. et al. CD19-targeted CAR T cells in refractory systemic lupus erythematosus. N. Engl. J. Med. 385, 567\u2013569 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1765_CR100","doi-asserted-by":"publisher","first-page":"100238","DOI":"10.1016\/j.xcrm.2021.100238","volume":"2","author":"KG Maxwell","year":"2021","unstructured":"Maxwell, K. G. & Millman, J. R. Applications of iPSC-derived beta cells from patients with diabetes. Cell Rep. Med. 2, 100238 (2021).","journal-title":"Cell Rep. Med."},{"key":"1765_CR101","first-page":"186","volume":"8","author":"L Fang","year":"2017","unstructured":"Fang, L., Murphy, A. J. & Dart, A. M. A clinical perspective of anti-fibrotic therapies for cardiovascular disease. Front. Pharm. 8, 186 (2017).","journal-title":"Front. Pharm."},{"key":"1765_CR102","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41586-019-1546-z","volume":"573","author":"H Aghajanian","year":"2019","unstructured":"Aghajanian, H. et al. Targeting cardiac fibrosis with engineered T cells. Nature 573, 430\u2013433 (2019).","journal-title":"Nature"},{"key":"1765_CR103","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.abm0594","volume":"375","author":"JG Rurik","year":"2022","unstructured":"Rurik, J. G. et al. CAR T cells produced in vivo to treat cardiac injury. Science 375, 91\u201396 (2022).","journal-title":"Science"},{"key":"1765_CR104","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1002\/stem.3449","volume":"39","author":"S Pouyanfard","year":"2021","unstructured":"Pouyanfard, S. et al. Human induced pluripotent stem cell-derived macrophages ameliorate liver fibrosis. Stem Cells 39, 1701\u20131717 (2021).","journal-title":"Stem Cells"},{"key":"1765_CR105","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1161\/CIRCRESAHA.121.318005","volume":"128","author":"JG Rurik","year":"2021","unstructured":"Rurik, J. G., Aghajanian, H. & Epstein, J. A. Immune cells and immunotherapy for cardiac injury and repair. Circ. Res 128, 1766\u20131779 (2021).","journal-title":"Circ. Res"},{"key":"1765_CR106","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1126\/science.1149726","volume":"318","author":"A Czechowicz","year":"2007","unstructured":"Czechowicz, A., Kraft, D., Weissman, I. L. & Bhattacharya, D. Efficient transplantation via antibody-based clearance of hematopoietic stem cell niches. Science 318, 1296\u20131299 (2007).","journal-title":"Science"},{"key":"1765_CR107","first-page":"2442","volume":"113","author":"CU Louis","year":"2009","unstructured":"Louis, C. U. et al. Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. Blood, J. Am. Soc. Hematol. 113, 2442\u20132450 (2009).","journal-title":"Blood, J. Am. Soc. Hematol."},{"key":"1765_CR108","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1182\/blood.V94.4.1237","volume":"94","author":"DC Matthews","year":"1999","unstructured":"Matthews, D. C. et al. Phase I study of 131I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood 94, 1237\u20131247 (1999).","journal-title":"Blood"},{"key":"1765_CR109","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-018-08201-x","volume":"10","author":"A Czechowicz","year":"2019","unstructured":"Czechowicz, A. et al. Selective hematopoietic stem cell ablation using CD117-antibody\u2013drug-conjugates enables safe and effective transplantation with immunity preservation. Nat. Commun. 10, 1\u201312 (2019).","journal-title":"Nat. Commun."},{"key":"1765_CR110","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1126\/science.abc6270","volume":"370","author":"JasperZ Williams","year":"2020","unstructured":"Williams, JasperZ. et al. Precise T cell recognition programs designed by transcriptionally linking multiple receptors. Science 370, 1099\u20131104 (2020).","journal-title":"Science"},{"key":"1765_CR111","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.jcyt.2018.11.009","volume":"21","author":"C Roddie","year":"2019","unstructured":"Roddie, C., O\u2019Reilly, M., Dias Alves Pinto, J., Vispute, K. & Lowdell, M. Manufacturing chimeric antigen receptor T cells: issues and challenges. Cytotherapy 21, 327\u2013340 (2019).","journal-title":"Cytotherapy"},{"key":"1765_CR112","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1038\/498S17a","volume":"498","author":"BL Levine","year":"2013","unstructured":"Levine, B. L. & June, C. H. Perspective: assembly line immunotherapy. Nature 498, S17 (2013).","journal-title":"Nature"},{"key":"1765_CR113","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41551-018-0246-6","volume":"2","author":"A Aijaz","year":"2018","unstructured":"Aijaz, A. et al. Biomanufacturing for clinically advanced cell therapies. Nat. Biomed. Eng. 2, 362\u2013376 (2018).","journal-title":"Nat. Biomed. Eng."},{"key":"1765_CR114","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","volume":"4","author":"BL Levine","year":"2017","unstructured":"Levine, B. L., Miskin, J., Wonnacott, K. & Keir, C. Global manufacturing of CAR T cell therapy. Mol. Ther. Methods Clin. Dev. 4, 92\u2013101 (2017).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"1765_CR115","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/d41587-021-00027-1","volume":"40","author":"C Sheridan","year":"2021","unstructured":"Sheridan, C. Off-the-shelf, gene-edited CAR-T cells forge ahead, despite safety scare. Nat. Biotechnol. 40, 5\u20138 (2021).","journal-title":"Nat. Biotechnol."},{"key":"1765_CR116","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.jcyt.2019.01.003","volume":"21","author":"RP Harrison","year":"2019","unstructured":"Harrison, R. P., Zylberberg, E., Ellison, S. & Levine, B. L. Chimeric antigen receptor-T cell therapy manufacturing: modelling the effect of offshore production on aggregate cost of goods. Cytotherapy 21, 224\u2013233 (2019).","journal-title":"Cytotherapy"},{"key":"1765_CR117","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","volume":"19","author":"S Depil","year":"2020","unstructured":"Depil, S., Duchateau, P., Grupp, S. A., Mufti, G. & Poirot, L. \u2018Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges. Nat. Rev. Drug Discov. 19, 185\u2013199 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1765_CR118","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41571-021-00485-1","volume":"18","author":"AM DiNofia","year":"2021","unstructured":"DiNofia, A. M. & Grupp, S. A. Will allogeneic CAR T cells for CD19+ malignancies take autologous CAR T cells \u2018off the shelf\u2019? Nat. Rev. Clin. Oncol. 18, 195\u2013196 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1765_CR119","doi-asserted-by":"publisher","first-page":"e9158","DOI":"10.15252\/emmm.201809158","volume":"10","author":"A Pfeiffer","year":"2018","unstructured":"Pfeiffer, A. et al. In vivo generation of human CD19-CAR T cells results in B-cell depletion and signs of cytokine release syndrome. EMBO Mol. Med. 10, e9158 (2018).","journal-title":"EMBO Mol. Med."},{"key":"1765_CR120","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1016\/j.ymthe.2020.05.005","volume":"28","author":"S Agarwal","year":"2020","unstructured":"Agarwal, S. et al. In vivo generation of CAR T cells selectively in human CD4+ lymphocytes. Mol. Ther. 28, 1783\u20131794 (2020).","journal-title":"Mol. Ther."},{"key":"1765_CR121","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00508-1","volume":"11","author":"W Nawaz","year":"2021","unstructured":"Nawaz, W. et al. AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia. Blood Cancer J. 11, 119 (2021).","journal-title":"Blood Cancer J."},{"key":"1765_CR122","unstructured":"Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use (FDA, 2020); https:\/\/www.fda.gov\/media\/109176\/download"},{"key":"1765_CR123","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.immuni.2016.05.014","volume":"44","author":"AD Posey Jr.","year":"2016","unstructured":"Posey, A. D. Jr. et al. Engineered CAR T cells targeting the cancer-associated Tn-glycoform of the membrane mucin MUC1 control adenocarcinoma. Immunity 44, 1444\u20131454 (2016).","journal-title":"Immunity"},{"key":"1765_CR124","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41586-021-04061-6","volume":"599","author":"M Yarmarkovich","year":"2021","unstructured":"Yarmarkovich, M. et al. Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs. Nature 599, 477\u2013484 (2021).","journal-title":"Nature"},{"key":"1765_CR125","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1126\/science.aba6527","volume":"369","author":"MJ Lajoie","year":"2020","unstructured":"Lajoie, M. J. et al. Designed protein logic to target cells with precise combinations of surface antigens. Science 369, 1637\u20131643 (2020).","journal-title":"Science"},{"key":"1765_CR126","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.cels.2020.08.002","volume":"11","author":"R Dannenfelser","year":"2020","unstructured":"Dannenfelser, R. et al. Discriminatory power of combinatorial antigen recognition in cancer T cell therapies. Cell Syst. 11, 215\u2013228 (2020).","journal-title":"Cell Syst."},{"key":"1765_CR127","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1097\/TP.0000000000002242","volume":"102","author":"B Ezekian","year":"2018","unstructured":"Ezekian, B. et al. Contemporary strategies and barriers to transplantation tolerance. Transplantation 102, 1213\u20131222 (2018).","journal-title":"Transplantation"},{"key":"1765_CR128","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1016\/j.bbmt.2015.05.001","volume":"21","author":"SO Ciurea","year":"2015","unstructured":"Ciurea, S. O. et al. Complement-binding donor-specific anti-HLA antibodies and risk of primary graft failure in hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 21, 1392\u20131398 (2015).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"1765_CR129","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nri3225","volume":"12","author":"SH Sacks","year":"2012","unstructured":"Sacks, S. H. & Zhou, W. The role of complement in the early immune response to transplantation. Nat. Rev. Immunol. 12, 431\u2013442 (2012).","journal-title":"Nat. Rev. Immunol."},{"key":"1765_CR130","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1097\/CJI.0b013e31824e7f43","volume":"35","author":"C Liu","year":"2012","unstructured":"Liu, C. et al. Agonistic antibody to CD40 boosts the antitumor activity of adoptively transferred T cells in vivo. J. Immunother. 35, 276\u2013282 (2012).","journal-title":"J. Immunother."},{"key":"1765_CR131","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10097-0","volume":"10","author":"PA Baeuerle","year":"2019","unstructured":"Baeuerle, P. A. et al. Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response. Nat. Commun. 10, 2087 (2019).","journal-title":"Nat. Commun."},{"key":"1765_CR132","doi-asserted-by":"publisher","first-page":"6548","DOI":"10.4049\/jimmunol.177.9.6548","volume":"177","author":"LA Johnson","year":"2006","unstructured":"Johnson, L. A. et al. Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes. J. Immunol. 177, 6548\u20136559 (2006).","journal-title":"J. Immunol."},{"key":"1765_CR133","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1158\/2326-6066.CIR-17-0207","volume":"6","author":"VYS Oei","year":"2018","unstructured":"Oei, V. Y. S. et al. Intrinsic functional potential of NK-cell subsets constrains retargeting driven by chimeric antigen receptors. Cancer Immunol. Res 6, 467\u2013480 (2018).","journal-title":"Cancer Immunol. Res"},{"key":"1765_CR134","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.stem.2018.06.002","volume":"23","author":"Y Li","year":"2018","unstructured":"Li, Y., Hermanson, D. L., Moriarity, B. S. & Kaufman, D. S. Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity. Cell Stem Cell 23, 181\u2013192(2018).","journal-title":"Cell Stem Cell"},{"key":"1765_CR135","doi-asserted-by":"publisher","first-page":"117580","DOI":"10.1016\/j.lfs.2020.117580","volume":"254","author":"M Sadeghzadeh","year":"2020","unstructured":"Sadeghzadeh, M. et al. Dendritic cell therapy in cancer treatment; the state-of-the-art. Life Sci. 254, 117580 (2020).","journal-title":"Life Sci."},{"key":"1765_CR136","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20658-3","volume":"12","author":"S Iriguchi","year":"2021","unstructured":"Iriguchi, S. et al. A clinically applicable and scalable method to regenerate T-cells from iPSCs for off-the-shelf T-cell immunotherapy. Nat. Commun. 12, 430 (2021).","journal-title":"Nat. Commun."},{"key":"1765_CR137","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/s41577-018-0042-2","volume":"18","author":"CR Maldini","year":"2018","unstructured":"Maldini, C. R., Ellis, G. I. & Riley, J. L. CAR T cells for infection, autoimmunity and allotransplantation. Nat. Rev. Immunol. 18, 605\u2013616 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"1765_CR138","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.3389\/fimmu.2020.01347","volume":"11","author":"M Rozenbaum","year":"2020","unstructured":"Rozenbaum, M. et al. Gamma-delta CAR-T cells show CAR-directed and independent activity against leukemia. Front Immunol. 11, 1347 (2020).","journal-title":"Front Immunol."},{"key":"1765_CR139","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1016\/j.celrep.2017.11.063","volume":"21","author":"M Chmielewski","year":"2017","unstructured":"Chmielewski, M. & Abken, H. CAR T cells releasing IL-18 convert to T-bet. Cell Rep. 21, 3205\u20133219 (2017).","journal-title":"Cell Rep."},{"key":"1765_CR140","doi-asserted-by":"publisher","first-page":"e994446","DOI":"10.4161\/2162402X.2014.994446","volume":"4","author":"M Koneru","year":"2015","unstructured":"Koneru, M., Purdon, T. J., Spriggs, D., Koneru, S. & Brentjens, R. J. IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors. Oncoimmunology 4, e994446 (2015).","journal-title":"Oncoimmunology"},{"key":"1765_CR141","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1158\/2326-6066.CIR-16-0376","volume":"5","author":"G Krenciute","year":"2017","unstructured":"Krenciute, G. et al. Transgenic expression of IL15 improves antiglioma activity of IL13R\u03b12-CAR T cells but results in antigen loss variants. Cancer Immunol. Res. 5, 571\u2013581 (2017).","journal-title":"Cancer Immunol. Res."},{"key":"1765_CR142","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1158\/1078-0432.CCR-16-1300","volume":"23","author":"J Ren","year":"2017","unstructured":"Ren, J. et al. Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. Clin. Cancer Res. 23, 2255\u20132266 (2017).","journal-title":"Clin. Cancer Res."},{"key":"1765_CR143","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-00462-8","volume":"7","author":"LJ Rupp","year":"2017","unstructured":"Rupp, L. J. et al. CRISPR\/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Sci. Rep. 7, 737 (2017).","journal-title":"Sci. Rep."},{"key":"1765_CR144","doi-asserted-by":"publisher","unstructured":"Rezaei, R. et al. Combination therapy with CAR T cells and oncolytic viruses: a new era in cancer immunotherapy. Cancer Gene Ther. https:\/\/doi.org\/10.1038\/s41417-021-00359-9 (2021).","DOI":"10.1038\/s41417-021-00359-9"},{"key":"1765_CR145","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1111\/cas.13027","volume":"107","author":"H Fukuhara","year":"2016","unstructured":"Fukuhara, H., Ino, Y. & Todo, T. Oncolytic virus therapy: a new era of cancer treatment at dawn. Cancer Sci. 107, 1373\u20131379 (2016).","journal-title":"Cancer Sci."},{"key":"1765_CR146","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.omto.2020.03.018","volume":"17","author":"A Aalipour","year":"2020","unstructured":"Aalipour, A. et al. Viral delivery of CAR targets to solid tumors enables effective cell therapy. Mol. Ther. Oncolytics 17, 232\u2013240 (2020).","journal-title":"Mol. Ther. Oncolytics"},{"key":"1765_CR147","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1038\/leu.2016.388","volume":"31","author":"S Hipp","year":"2017","unstructured":"Hipp, S. et al. A novel BCMA\/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo. Leukemia 31, 1743\u20131751 (2017).","journal-title":"Leukemia"},{"key":"1765_CR148","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","volume":"16","author":"S Bagchi","year":"2021","unstructured":"Bagchi, S., Yuan, R. & Engleman, E. G. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev. Pathol. 16, 223\u2013249 (2021).","journal-title":"Annu Rev. Pathol."},{"key":"1765_CR149","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1172\/JCI103949","volume":"38","author":"ED Thomas","year":"1959","unstructured":"Thomas, E. D., Lochte, H. L., Cannon, J. H., Sahler, O. D. & Ferrebee, J. W. Supralethal whole body irradiation and isologous marrow transplantation in man. J. Clin. Investig. 38, 1709\u20131716 (1959).","journal-title":"J. Clin. Investig."},{"key":"1765_CR150","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1056\/NEJM197905103001902","volume":"300","author":"PL Weiden","year":"1979","unstructured":"Weiden, P. L. et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N. Engl. J. Med. 300, 1068\u20131073 (1979).","journal-title":"N. Engl. J. Med."},{"key":"1765_CR151","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/nri3212","volume":"12","author":"BR Blazar","year":"2012","unstructured":"Blazar, B. R., Murphy, W. J. & Abedi, M. Advances in graft-versus-host disease biology and therapy. Nat. Rev. Immunol. 12, 443\u2013458 (2012).","journal-title":"Nat. Rev. Immunol."},{"key":"1765_CR152","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3389\/fimmu.2016.00100","volume":"7","author":"M Griffioen","year":"2016","unstructured":"Griffioen, M., van Bergen, C. A. & Falkenburg, J. Autosomal minor histocompatibility antigens: how genetic variants create diversity in immune targets. Front. Immunol. 7, 100 (2016).","journal-title":"Front. Immunol."},{"key":"1765_CR153","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1146\/annurev-immunol-102119-073227","volume":"39","author":"GR Hill","year":"2021","unstructured":"Hill, G. R., Betts, B. C., Tkachev, V., Kean, L. S. & Blazar, B. R. Current concepts and advances in graft-versus-host disease immunology. Annu. Rev. Immunol. 39, 19\u201349 (2021).","journal-title":"Annu. Rev. Immunol."},{"key":"1765_CR154","doi-asserted-by":"publisher","first-page":"4885","DOI":"10.1182\/blood-2004-12-4980","volume":"105","author":"E Tivol","year":"2005","unstructured":"Tivol, E., Komorowski, R. & Drobyski, W. R. Emergent autoimmunity in graft-versus-host disease. Blood 105, 4885\u20134891 (2005).","journal-title":"Blood"},{"key":"1765_CR155","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1182\/blood-2016-09-740431","volume":"129","author":"SR Wu","year":"2017","unstructured":"Wu, S. R. & Reddy, P. Tissue tolerance: a distinct concept to control acute GVHD severity. Blood 129, 1747\u20131752 (2017).","journal-title":"Blood"},{"key":"1765_CR156","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.cell.2016.03.001","volume":"165","author":"L Zitvogel","year":"2016","unstructured":"Zitvogel, L., Ayyoub, M., Routy, B. & Kroemer, G. Microbiome and anticancer immunosurveillance. Cell 165, 276\u2013287 (2016).","journal-title":"Cell"},{"key":"1765_CR157","doi-asserted-by":"publisher","first-page":"eabc4552","DOI":"10.1126\/science.abc4552","volume":"371","author":"GD Sepich-Poore","year":"2021","unstructured":"Sepich-Poore, G. D. et al. The microbiome and human cancer. Science 371, eabc4552 (2021).","journal-title":"Science"},{"key":"1765_CR158","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1126\/science.1240537","volume":"342","author":"S Viaud","year":"2013","unstructured":"Viaud, S. et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 342, 971\u2013976 (2013).","journal-title":"Science"},{"key":"1765_CR159","doi-asserted-by":"publisher","first-page":"111931","DOI":"10.18632\/oncotarget.22953","volume":"8","author":"MP Kuczma","year":"2017","unstructured":"Kuczma, M. P. et al. The impact of antibiotic usage on the efficacy of chemoimmunotherapy is contingent on the source of tumor-reactive T cells. Oncotarget 8, 111931 (2017).","journal-title":"Oncotarget"},{"key":"1765_CR160","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1146\/annurev-immunol-020711-074937","volume":"30","author":"K Honda","year":"2012","unstructured":"Honda, K. & Littman, D. R. The microbiome in infectious disease and inflammation. Annu. Rev. Immunol. 30, 759\u2013795 (2012).","journal-title":"Annu. Rev. Immunol."},{"key":"1765_CR161","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/s41586-019-0878-z","volume":"565","author":"T Tanoue","year":"2019","unstructured":"Tanoue, T. et al. A defined commensal consortium elicits CD8 T cells and anti-cancer immunity. Nature 565, 600\u2013605 (2019).","journal-title":"Nature"},{"key":"1765_CR162","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1056\/NEJMoa1900623","volume":"382","author":"JU Peled","year":"2020","unstructured":"Peled, J. U. et al. Microbiota as predictor of mortality in allogeneic hematopoietic-cell transplantation. N. Engl. J. Med. 382, 822\u2013834 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1765_CR163","doi-asserted-by":"publisher","first-page":"e94952","DOI":"10.1172\/jci.insight.94952","volume":"3","author":"M Uribe-Herranz","year":"2018","unstructured":"Uribe-Herranz, M. et al. Gut microbiota modulates adoptive cell therapy via CD8\u03b1 dendritic cells and IL-12. JCI Insight 3, e94952 (2018).","journal-title":"JCI Insight"},{"key":"1765_CR164","doi-asserted-by":"publisher","first-page":"S177","DOI":"10.1016\/j.bbmt.2018.12.319","volume":"25","author":"M Smith","year":"2019","unstructured":"Smith, M. et al. Intestinal microbiome analyses identify biomarkers for patient response to CAR T cell therapy. Biol. Blood Marrow Transplant. 25, S177 (2019).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"1765_CR165","unstructured":"Smith, M., et al. Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. Nat. Med. (in the press)."},{"key":"1765_CR166","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.gde.2020.11.007","volume":"66","author":"CL Nguyen","year":"2021","unstructured":"Nguyen, C. L., Docampo, M. D., van den Brink, M. R. & Markey, K. A. The role of the intestinal microbiota in allogeneic HCT: clinical associations and preclinical mechanisms. Curr. Opin. Genet. Dev. 66, 25\u201335 (2021).","journal-title":"Curr. Opin. Genet. Dev."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-01765-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-01765-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-01765-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T18:11:34Z","timestamp":1650478294000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-01765-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":166,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1765"],"URL":"https:\/\/doi.org\/10.1038\/s41591-022-01765-8","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"18 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.H.J. has received grant support from Novartis, and has patents related to CAR therapy with royalties paid from Novartis to the University of Pennsylvania. C.H.J. is also a scientific co-founder and holds equity in Capstan Therapeutics and Tmunity Therapeutics. C.H.J. serves on the board of AC Immune and is a scientific advisor to Alaunos, BluesphereBio, Cabaletta, Carisma, Cartography, Cellares, Cellcarta, Celldex, Danaher, Decheng, ImmuneSensor, Poseida, Verismo, Viracta, and WIRB-Copernicus group.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}